Core Viewpoint - Vivid Seats Inc. is implementing a $25 million cost reduction program to enhance long-term efficiency and adapt to current market challenges, while maintaining a positive outlook on the live events industry as a long-term opportunity [2][3]. Financial Performance - For Q2 2025, Vivid Seats reported a Marketplace Gross Order Value (GOV) of $685.5 million, a decrease of 31% from $998.1 million in Q2 2024 [6]. - Revenues for Q2 2025 were $143.6 million, down 28% from $198.3 million in Q2 2024 [6]. - The company experienced a net loss of $263.3 million in Q2 2025, compared to a net loss of $1.2 million in Q2 2024 [6]. - Adjusted EBITDA for Q2 2025 was $14.4 million, down from $44.2 million in Q2 2024 [6]. Operational Metrics - Marketplace orders totaled 2,173 in Q2 2025, down from 3,097 in Q2 2024 [5]. - Resale orders were 97 in Q2 2025, slightly down from 101 in Q2 2024 [5]. - The company faced 47,845 event cancellations in Q2 2025, compared to 52,392 in Q2 2024 [8]. Cost Reduction Strategy - The $25 million cost reduction program aims to right-size the organization and improve efficiency, with full implementation expected by the end of 2025 [2][3]. - A portion of the savings will be reinvested to stabilize revenue streams as the company looks towards 2026 and beyond [3]. Market Outlook - Despite current pressures on consumer spending and competitive intensity, the company views the live events sector as a durable long-term opportunity [2]. - The company anticipates positive cash flow in Q3 2025, driven by seasonal improvements and a belief that June's industry volume softness was atypical [3]. Stock Activity - A 1-for-20 reverse stock split of Class A and Class B common stock was approved, effective August 6, 2025, to enhance stock performance [10]. Company Overview - Vivid Seats, founded in 2001, is a leading online ticket marketplace focused on connecting fans with live events, offering a wide selection of tickets and a rewards program [12].

Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its common stock price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 5:01 p.m. Eastern Standard Time on August 4, 2025, with trading on a split-adjusted basis starting August 5, 2025 [1]. - The split will convert ten existing shares into one new share, reducing the number of outstanding shares from approximately 16,760,978 to about 1,676,098 [2]. - Stockholders entitled to fractional shares will receive cash equivalent to the fractional amount multiplied by the closing price on August 1, 2025 [2]. Group 2: Administrative Aspects - Computershare, Inc. will serve as the exchange agent for the reverse stock split, and stockholders will not need to take action to receive their post-split shares [3]. - The CUSIP number for the company will change to 55453W501 effective at the time of the split [4]. Group 3: Company Overview - MacKenzie Realty Capital, Inc. is a West Coast-focused REIT, aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has maintained a dividend payout every year since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].

The struggling real estate tech specialist is considering a reverse stock split. Investors eagerly shut the door on real estate transaction platform developer Opendoor Technologies (OPEN -7.87%) on Monday. They didn't take kindly to news of an important vote on the company's future, and sent the share price down by almost 8% on the day. Meanwhile, the S&P 500 (^GSPC 0.02%) flatlined across the session, indicating that many other stocks would have been better pickups. Decision delayed In its words, "an appro ...

As filed with the Securities and Exchange Commission on July 28, 2025 Registration No. 333-286850 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Safe & Green Holdings Corp. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 5030 95-4463937 (Primary Standard Industrial Classification Code Number) 990 Biscayne Blvd., Suite 501 Miami, Florida 3313 ...

Core Viewpoint - Opendoor Technologies Inc. has announced the adjournment of its Special Meeting of Stockholders to August 27, 2025, to allow more time to assess market conditions and the company's stock price [1][5]. Proposal and Compliance - The Special Meeting was originally convened to consider two proposals regarding a discretionary reverse stock split of the company's common stock, which would only be pursued if deemed beneficial by the Board of Directors [2]. - The company received a notice from Nasdaq in May indicating non-compliance with listing rules due to its stock price being below $1.00 per share for 30 consecutive business days [3]. - To regain compliance, Opendoor's stock price must be at least $1.00 per share for a minimum of 10 consecutive business days by November 24, 2025 [4]. Meeting Details - The adjourned Special Meeting will continue to be held online, and stockholders are encouraged to vote during the adjournment period [6][7]. - The record date for stockholders entitled to vote remains June 4, 2025 [7].

Core Viewpoint - Vaxart, Inc. is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirements following a trading suspension due to non-compliance [2][3][4] Group 1: Reverse Stock Split Proposal - The preliminary proxy statement includes a proposal for a reverse stock split with a ratio of not less than 1-for-5 and not more than 1-for-20 [9] - The proposal aims to reduce the number of authorized shares of common stock in proportion to the reverse stock split [4][9] - The Board of Directors believes that compliance with Nasdaq listing requirements is essential for liquidity and capital raising [3] Group 2: Stockholder Engagement - A special meeting of stockholders is scheduled for September 5, 2025, to discuss the reverse stock split proposal [5] - Management plans to hold a live stockholder fireside chat to address questions and explain the necessity of the reverse stock split [3][8] Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [6] - The company's vaccine candidates include those for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [6]

Core Insights - Lucid Motors received a significant boost with Uber Technologies announcing a $300 million investment to form a robotaxi partnership, leading to a stock increase of over 40% [1][3] - The partnership aims to deploy a fleet of 20,000 Lucid vehicles over the next six years, utilizing Lucid's Gravity SUV and Nuro's level 4 autonomy system [4][6] - Lucid's recent developments, including the potential reverse stock split, are aimed at enhancing its attractiveness to institutional investors [9][12] Investment Partnership - The collaboration with Uber involves creating a new robotaxi service that leverages Lucid's advanced vehicle technology and Uber's extensive global network [3][7] - The first prototype of the Lucid-Nuro robotaxi is already operational, indicating progress in the partnership [4] - This investment validates Lucid's technology and positions it favorably in the autonomous vehicle market, potentially increasing demand for its products [9][13] Production and Market Strategy - Lucid aims to deliver approximately 20,000 vehicles in 2025, a significant increase from the 6,500 vehicles delivered in the first half of the year [6] - The partnership with Uber is seen as a critical step in proving Lucid's technology and market demand, especially in comparison to competitors like Rivian [7][8] Reverse Stock Split - Lucid has filed for a reverse stock split at a ratio of 1:10, which will consolidate shares and increase the trading price without changing market capitalization [10][11] - This move is intended to make Lucid's stock more appealing to larger institutional investors who often have minimum price thresholds for investment [12] - While reverse stock splits are generally viewed negatively, Lucid's situation does not indicate immediate financial distress [11][13]

Core Viewpoint - Generation Bio Co. announced a 1-for-10 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 pm Eastern Time on July 21, 2025, and trading on a split-adjusted basis will begin on July 22, 2025 [1][2]. - The number of issued and outstanding shares will decrease from approximately 67.3 million to approximately 6.7 million [3]. - No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares [4]. Group 2: Company Background - Generation Bio is focused on developing therapeutics for T cell-driven autoimmune diseases using cell-targeted lipid nanoparticles to deliver small interfering RNA to T cells [7]. - The company's innovative approach aims to address historically undruggable disease-driving genes in autoimmunity [7].

Group 1 - Lucid's stock increased by 46.72% in premarket trading following Uber's announcement of a $300 million investment in the electric vehicle maker as part of a six-year robotaxi partnership [1][4] - Under the agreement, Uber will deploy at least 20,000 Lucid vehicles equipped with Nuro's self-driving technology over a six-year period, with the first robotaxis expected to launch in a major U.S. city next year [3][4] - The partnership marks a significant shift for Lucid from focusing on luxury consumer vehicles to entering the commercial robotaxi market [5] Group 2 - Lucid's first robotaxi prototype is currently being tested at Nuro's Las Vegas proving grounds, with the vehicles set to be owned and operated by Uber or its fleet partners [6] - Lucid filed a preliminary proxy statement with the SEC regarding a special stockholders' meeting to authorize a 1-for-10 reverse stock split, which the company believes will make its common stock more attractive to investors [7] - The reverse stock split will not affect stockholders' ownership interests or voting power, except for potential cash payments for fractional shares, and requires majority approval from votes cast at the special stockholders' meeting [8]

Core Points - Ikena Oncology, Inc. announced the results of its annual stockholder meeting, where stockholders approved the merger with Inmagene Biopharmaceuticals [2][3] - The combined company will be named ImageneBio, Inc. and will trade on Nasdaq under the ticker symbol "IMA" [3] - A 1-for-12 reverse stock split will be executed, reducing the number of outstanding shares from approximately 48.2 million to about 4 million [3][4] Company Overview - Ikena Oncology focuses on developing differentiated therapies targeting cancer growth, spread, and therapeutic resistance [6] - Inmagene Biopharmaceuticals is a clinical-stage biotechnology company developing therapeutics for immunological and inflammatory diseases, with its lead asset IMG-007 recently completing Phase 2a trials [5][6] Merger Details - The merger allows for the issuance of shares of Ikena's common stock to Inmagene shareholders and investors involved in the financing concurrent to the merger [3] - The reverse stock split is expected to be effective around the end of July, prior to the merger closing [3][4] - The new CUSIP number for the combined company's common stock will be 45175G 207 [3] Product Information - IMG-007 is a humanized, subcutaneously administered monoclonal antibody targeting OX40, showing promising results in clinical trials for atopic dermatitis and alopecia areata [7] - The drug demonstrated a half-life of 34.7 days, supporting infrequent dosing [7] - In clinical trials, IMG-007 exhibited sustained clinical activity and was well tolerated, with no significant adverse effects reported [7]